Skip to content

Micro Ribonucleic Acid (miRNA) Expression and Inflammatory Factors in Patients With Parkinson's and Periodontal Disease

Relationship Between Micro Ribonucleic Acid (miRNA) Expression and Inflammatory Factors in Patients With Parkinson's and Periodontal Disease

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07099378
Enrollment
51
Registered
2025-08-01
Start date
2025-08-01
Completion date
2026-02-01
Last updated
2025-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontal Diseases Inflammation

Keywords

periodontal disease miRNA

Brief summary

MicroRNAs are important regulators of the immune and inflammatory response to bacterial pathogens during periodontal disease.The aim of this study was to evaluate the possible miRNA type for Parkinson's in saliva of orally healthy individuals.

Detailed description

A total of 51 individuals, 35 systemically healthy and 16 with Parkinson's disease and both dental and periodontal health, were included in the study.Clinical periodontal parameters, DMFT data and salivary flow rates were recorded.Unstimulated saliva samples were taken from each participant and miRNA was evaluated by RT-qPCR method.ELISA method was used to measure TNF α values in collected saliva and serum samples.

Interventions

OTHERSaliva and Serum

Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff from each participant.Saliva and serum were then stored at -80 °C until analysis.

Sponsors

Medipol University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* dentally and periodontally healthy * Systemically healthy with no uncontrolled chronic and/or autoimmune disease * No systemic, neurological, or autoimmune disease in addition to Parkinson's disease.

Exclusion criteria

* history of regular use of systemic antibiotics anti-inflammatory, or antioxidant drugs (previous 3 months) * nonsurgical periodontal treatment (previous 6 months) * surgical periodontal treatment (previous 12 months) * presence of\<20 teeth * current medications affecting gingival health (calcium channel blockers, phenytoin, cyclosporine, and hormone replacement therapy) * diabetes * diagnosis of rheumatoid arthritis * pregnancy * lactating * smoking * excessive alcohol consumption.

Design outcomes

Primary

MeasureTime frameDescription
1. Pocket probing depth6 monthsMeasurement of the depth of a sulcus or periodontal pocket determined by measuring distance from a gingival margin to the base of the sulcus or pocket with a calibrated periodontal probe.
2.Clinical attachment level6 monthsClinical attachment level (or loss, CAL) is a more accurate indicator of the periodontal support around a tooth than probing depth alone. CAL is measured from a fixed point on the tooth that does not change, the CEJ. To calculate CAL, two measurements are needed: distance from the gingival margin to the CEJ and probing depth. In recession: probing depth (+) gingival margin to the CEJ (add). In tissue overgrowth: probing depth (-) gingival margin to the CEJ (subtract)
3.Bleeding on probing6 monthsreferring to bleeding that is induced by gentle manipulation of the tissue at the depth of the gingival sulcus, or interface between the gingiva and a tooth.

Secondary

MeasureTime frameDescription
4.Saliva and serum samples processing and analyses1 monthELISA method will be used to measure TNF-α values in collected saliva and serum samples.RT-qPCR based miRNA gene expression analyses will be performed with 2-step qRT-PCR Kits (Thermofisher Scientific, MA, USA).

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026